Clinical trial
dnaJ Peptide for Relieving Rheumatoid Arthritis
NCT00000435 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00000435 |
|---|---|
| Title | dnaJ Peptide for Relieving Rheumatoid Arthritis |
| Official title | A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA) |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | dnaJ peptide, None-placebo |
| Enrollment | 160 |
| Start date | Sep 1, 1999 |
| Completion | Sep 1, 2004 |
| First posted | Jan 24, 2000 |
| Last update posted | Jul 31, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: